Q2 2026 saw robust revenue growth, strong U.S. and international demand for VYJUVEK, and progress in clinical and regulatory milestones. Net revenue rose 24% year-over-year, with over 730 U.S. reimbursement approvals and continued global expansion.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.